Chronic Lower Back Pain

3
Pipeline Programs
3
Companies
2
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Braeburn Pharmaceuticals
BRIXADIApproved
buprenorphine
Braeburn Pharmaceuticals
Partial Opioid Agonist [EPC]subcutaneous2023

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Braeburn Pharmaceuticals
Braeburn PharmaceuticalsPA - Plymouth Meeting
1 program
1
1
buprenorphinePhase 31 trial
Active Trials
NCT02946073Completed1,053Est. Feb 2019
Camurus
CamurusSweden - Lund
1 program
1
buprenorphinePhase 3
Aspen Medical products
1 program
In-elastic lumbar braceN/A1 trial
Active Trials
NCT02241824Unknown36Est. Dec 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Braeburn Pharmaceuticalsbuprenorphine
Aspen Medical productsIn-elastic lumbar brace

Clinical Trials (2)

Total enrollment: 1,089 patients across 2 trials

Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain

Start: Sep 2016Est. completion: Feb 20191,053 patients
Phase 3Completed
NCT02241824Aspen Medical productsIn-elastic lumbar brace

Chronic Opioid Use in Low Back Pain and Lumbar Orthosis Intervention

Start: Jan 2015Est. completion: Dec 201636 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space